99%+ HPLC Pure | Batch-Specific Third-Party COAs | Free Shipping $250+ | Same-Day Shipping Before 2PM CT | Ships Across the US

Kynetide Research Team | Jul 17

FDA Approves LIPFENDRA: First Oral Macrocyclic Peptide for Cholesterol

A 2026 market-news look at Merck's newly FDA-approved LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor, and what its macrocyclic peptide design means for the future of peptide drug research and sourcing.

A Once-Daily Pill Joins the PCSK9 Inhibitor Class

On July 16, 2026, the FDA approved Merck's LIPFENDRA (enlicitide), the first oral medication in the PCSK9 inhibitor class used to lower LDL cholesterol. Until now, PCSK9 inhibitors have only been available as injectable biologics; LIPFENDRA reaches patients as a once-daily 20 mg tablet. The approval covers adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), as an add-on to diet and exercise.

A Macrocyclic Peptide That Blocks PCSK9 From Binding LDL Receptors

What makes LIPFENDRA notable for peptide researchers is its chemistry: enlicitide is a macrocyclic peptide, a ring-shaped peptide structure engineered to combine the target specificity of a biologic drug with the oral bioavailability of a small molecule. Enlicitide binds PCSK9 and blocks its interaction with LDL receptors on liver cells, the same mechanism used by injectable monoclonal-antibody PCSK9 inhibitors, but delivered as a swallowed tablet instead of an injection.

What the Phase 3 Data Showed

The approval rests on two Phase 3 trials in the CORALreef program. In CORALreef Lipids, enlicitide reduced LDL-C by a placebo-adjusted 56% at week 24; in CORALreef HeFH, the reduction was 59%. Both studies also reported meaningful drops in non-HDL cholesterol and apolipoprotein B. The most common side effects in the HeFH trial were diarrhea (7% versus 2% for placebo) and dizziness (9% versus 4% for placebo). A separate outcomes trial is still underway to determine whether enlicitide reduces cardiovascular events.

What an Oral Macrocyclic Peptide Approval Means for Peptide Research Sourcing

LIPFENDRA's approval is a milestone for macrocyclic peptide chemistry as a drug-development platform, showing that carefully engineered peptides can reach oral bioavailability against targets once thought to require injectable biologics. Enlicitide is not a compound in Kynetide's catalog; it is an FDA-approved prescription medicine, not a research peptide. But the underlying chemistry is a reminder of why identity and purity controls matter across peptide research generally: as more labs explore macrocyclic and constrained-peptide designs, third-party HPLC testing and a batch-specific Certificate of Analysis are what let researchers trust exactly what they are working with. Kynetide's products are supplied strictly for in-vitro and laboratory research use. They are not drugs, cosmetics, or supplements, and are not intended for human or veterinary use.

FAQ: What is LIPFENDRA (enlicitide)?

LIPFENDRA is Merck's brand name for enlicitide, a macrocyclic peptide approved by the FDA on July 16, 2026 as the first once-daily oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

FAQ: Does Kynetide Sell Enlicitide or PCSK9 Research Peptides?

No. LIPFENDRA (enlicitide) is an FDA-approved prescription drug, not a research compound, and it is not part of Kynetide's catalog. This article is provided as market news for researchers tracking developments in peptide-based drug design.

About This Article

This content was prepared and reviewed by the Kynetide Research Team — PhD-level biochemists, peptide chemists, and laboratory scientists with backgrounds in pharmaceutical research, analytical chemistry, and regulatory science. Our team reviews primary literature, clinical studies, and regulatory filings to provide accurate, science-first content for laboratory investigators.

All Kynetide content is reviewed for scientific accuracy before publication. For research inquiries, contact us at support@kynetide.com.

Kynetide Research Team

More Posts

FDA's September 2026 Warning-Letter Sweep: What It Means for Research Peptide BuyersFDA's September 2026 Warning-Letter Sweep: What It Means for Research Peptide Buyers
FDA's September 2026 Warning-Letter Sweep: What It Means for Research Peptide Buyers

On September 1, 2026, the FDA published a coordinated set of warning letters targeting five online peptide vendors. The sweep signals that the agency is shifting from case-by-case enforcement to sector-wide scrutiny — and that a "research use only" disclaimer is no longer a regulatory shield. Here is what the letters actually say, which vendors and products were named, and what it means for labs sourcing peptides today.

The Copper Peptide (GHK-Cu) Injection Trend: What the Research Actually ShowsThe Copper Peptide (GHK-Cu) Injection Trend: What the Research Actually Shows
The Copper Peptide (GHK-Cu) Injection Trend: What the Research Actually Shows

Copper peptide serums have been a skincare staple for years, but a new trend has emerged: people are drawing GHK-Cu into syringes and injecting it at home in pursuit of firmer skin, thicker hair, and slower aging. Here's what the research actually supports, what remains unknown, and why sourcing quality matters for anyone studying this compound.

New Bill Would Direct the VA to Study Peptide Therapies for VeteransNew Bill Would Direct the VA to Study Peptide Therapies for Veterans
New Bill Would Direct the VA to Study Peptide Therapies for Veterans

On September 1, 2026, Rep. Nancy Mace introduced the PEPTIDES for Veterans Act, a bill directing the Department of Veterans Affairs to formally study peptide-based therapies for veterans receiving VA care. Here's what the bill actually does, and doesn't do, for the research community.

Peptides and Cancer Risk: What the Current Research Actually ShowsPeptides and Cancer Risk: What the Current Research Actually Shows
Peptides and Cancer Risk: What the Current Research Actually Shows

Peptides like BPC-157, TB-500, MOTS-c, KPV, epitalon, and semax have become some of the most searched compounds in longevity and biohacking circles. Social media has fueled claims that they speed healing, improve sleep, build muscle, and boost energy. But according to cancer researchers, the evidence behind many of these claims is thin, and there's an open scientific question that gets far less attention than the hype: could some peptides affect cancer risk?

Lab Tests Reveal Wild Dosing Swings in Black-Market PeptidesLab Tests Reveal Wild Dosing Swings in Black-Market Peptides
Lab Tests Reveal Wild Dosing Swings in Black-Market Peptides

An Australian lab that now spends half its time analyzing peptides bought online has found that black-market vials of a popular weight-loss peptide are just as likely to be overdosed as underdosed. The results add a new dimension to the safety debate around unapproved peptides and underscore why verified sourcing matters.

The "Looksmaxxing" Peptide Trend: What the Science Actually SaysThe "Looksmaxxing" Peptide Trend: What the Science Actually Says
The "Looksmaxxing" Peptide Trend: What the Science Actually Says

Peptides are being marketed on TikTok as a shortcut to a younger, sharper-looking face. A pharmaceutical sciences researcher explains why the hype is running well ahead of the evidence, and why sourcing and safety data matter more than ever.

Florida's Peptide Craze Is Booming — What a New Investigation FoundFlorida's Peptide Craze Is Booming — What a New Investigation Found
Florida's Peptide Craze Is Booming — What a New Investigation Found

A new Tampa Bay Times report finds that peptides have become one of Florida's fastest-growing health trends, with social media influencers driving demand for compounds marketed to ease joint pain, speed weight loss, and improve sleep. Compounding pharmacists like Dr. David Pino say order volumes have surged, raising fresh questions about oversight, purity, and who's actually formulating what people are injecting.

Trump Taps Dr. Heidi Overton to Lead the FDA — What It Could Mean for Peptide RegulationTrump Taps Dr. Heidi Overton to Lead the FDA — What It Could Mean for Peptide Regulation
Trump Taps Dr. Heidi Overton to Lead the FDA — What It Could Mean for Peptide Regulation

President Trump has picked Dr. Heidi Overton, a physician and White House health policy aide, as his nominee to lead the FDA. If confirmed by the Senate, she would inherit one of the agency's most closely watched open questions: what happens next for peptides like BPC-157 and TB-500 after this summer's advisory panel vote.

Who's Actually Watching for Peptide Side Effects?Who's Actually Watching for Peptide Side Effects?
Who's Actually Watching for Peptide Side Effects?

Peptides are everywhere on social media, but most of the unapproved products behind the hype have never been checked for what's actually in the vial. A new public-health review breaks down the safety gaps regulators are racing to close, and why sourcing verification matters more than ever.